Ibex Medical Analytics Announces Expansion of its Biopharma Business, Extending AI Pathology Platform into Early Biomarker Development

Portfolio CompaniesLIP Fund IINewHealth Ventures
Written By Federico de Mateo

Ibex Medical Analytics, the global leader in clinical-grade AI-powered pathology, today announced a significant expansion of its biopharma business. Building on its successful collaborations in late-stage biomarker development, Ibex is now extending its platform into earlier translational research, biomarker development, and trial-efficiency optimization.

Ibex’s high-performance AI platform—already deployed across more than 50 health systems worldwide and used in collaboration with major industry organizations such as Philips and Roche—now supports exploratory, preclinical, and clinical evidence generation, while providing a seamless foundation for future companion diagnostic (CDx) programs.

Read More on Yahoo! Finance
Federico de Mateo
Previous

Quantum Art raises $100 million Series A to scale full-stack quantum systems
Next

Tabnine Wins InfoWorld Technology of the Year Award 2025 for Software Development Tools